This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Stocks Setting Up to Break Out

Jazz Pharmaceuticals

If you're looking for a biotech star that's starting to break out, then take a look at Jazz Pharmaceuticals (JAZZ - Get Report), a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. This stock is off to a blazing start in 2011, with shares up over 88%.

A Piper Jaffray analyst recently started coverage on JAZZ with an overweight rating and a price target of $51 a share, which is well above its current price near $37 a share. The analyst is bullish on the future sales of Xyrem, a narcolepsy drug that costs about $30,000 a year.

If you take a look at the chart for Jazz, you'll see that this stock biotech player has already started to break out above some past overhead resistance at $36.47 a share. What I love about this breakout in Jazz is that it has started on huge upside volume. Volume on Thursday, which was the first day of the breakout, clocked in at 1.3 million shares, which is well above the three-month average volume of 781,300 shares. In fact, the volume for the entire past month has been very strong when you compare the action on the up days versus the down days.

What's even more bullish about this move on JAZZ is that the stock is now trading just one point off of its all-time high of $38 a share. This means that just about everyone who has bought this stock is making money. It also means that momentum traders are going to circle around this stock since it is displaying so much strength and hitting new highs almost daily.

It's worth noting that the current short interest on JAZZ is rather large at around 13.4% of the tradable float. The short-sellers have also been increasing their bets from the last reporting period by 7.7%, or by about 187,000 shares. Nothing is worse for a short-seller than being short a stock like JAZZ which is now trading at all-time highs.
4 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
CDE $7.44 0.00%
GURE $1.48 0.00%
JAZZ $152.00 0.00%
AAPL $95.03 0.21%
FB $116.73 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs